Bayer counters bad birth control info

Share this article:
The company ran a TV ad supporting a new unbranded website,, which offers information on the comparative effectiveness of different birth control methods, risks and benefits and frequently asked questions on the topic. There's also a “Learn more” button that takes the user to an external site for Bayer birth control drugs Yaz, Yasmin and Mirena.

The aim of the campaign, said deputy director, external product comms Rose Talarico, is to “encourage women to get the full picture about their birth control.”

“Women today have many different birth control methods to choose from,” said Talrico, “and they often get information from a variety of sources, some of which may not be accurate, such as blogs, coworkers, TV and more. Since making a misinformed decision about birth control can lead to unnecessary risks, it's important that women have access to all the information available in a straightforward and educational format.”

The TV spot, by Young & Rubicam, plays on the parable of the three blind men and the elephant, depicting three blindfolded young women touching a rhinoceros (kids, don't try this at home). “It's a pillar,” says one. “It's a wall,” says a second.

“Having only one point of view on anything can be misleading,” says the narrator, before hailing the company as “a leader in the field of contraception” and urging women to “get the complete picture” at the website.

In February, 2009, Bayer agreed to spend $20 million running corrective ads for Yaz and to submit future ads to FDA for preclearance for six years as part of a settlement with the agency and 27 state attorneys general over two TV ads that FDA said broadened the indication and minimized risks.

The ads, which ran in 2007 and 2008, are credited with helping more than double sales of the drug, from $262 million in 2007 to $616 million in 2008, according to IMS Health data.
Share this article:

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.